Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01943630
Recruitment Status : Unknown
Verified October 2016 by BioMAS Ltd.
Recruitment status was:  Recruiting
First Posted : September 17, 2013
Last Update Posted : November 1, 2016
Information provided by (Responsible Party):
BioMAS Ltd

Brief Summary:
The purpose of this double blind study is to determine whether topical 15% AS101 gel is effective and safe as compared to vehicle in the treatment of external genital warts in women.

Condition or disease Intervention/treatment Phase
External Genital Warts Drug: 15% AS101 gel Drug: Vehicle Phase 2

Detailed Description:

Females with external genital warts who meet the eligibility criteria will be randomly allocated in a blinded manner in 1:1 ratio to one of the 2 following study arms: (1) AS101 15% gel or (2) Vehicle. The patients will apply the study drug at home once daily (overnight) until complete clearance of external genital warts or for up to 14 weeks (98 days).

During therapy all patients will return to the clinic every 2 weeks plus/minus 3 days of the treatment visit for clinical assessments of the treated area.

At week 6 of treatment the investigator will evaluate the treated area for all patients. If the investigator determines that there is no change in the disease spread area or lesion number compared to Day 1, study therapy is to be discontinued prior to 14 weeks (98 days) of treatment and the patient will be considered as not cleared. Last observation carried forward (LOCF) method will be used to analyze such patients.

Patients who at week 6 were evaluated by the investigator to have a change in the disease spread area or lesion number compared to Day 1, will continue treatment until complete clearance of warts or up to a maximum of 14 weeks (98 days).

Patients who were evaluated during any of the treatment visits with complete clearance will stop to apply the study therapy, continue to be followed once per 4 weeks for 84 days (12 weeks) for safety and recurrence evaluation. Patients who completed treatment with partial clearance or patients who discontinued for reasons of other than complete clearance will be followed 28 days after discontinuation for disease progression and reference to other therapy if was recommended.

Should significant irritation or any other skin adverse reaction occur during the treatment period, study therapy may be held for up to 7 consecutive days on up to two separate occasions.

Unblinding: Patients will be revealed as to the nature of their treatment only after all patients have completed study.

In case of pregnancy or related serious adverse event the nature of the treatment will be revealed to the patient prior to end of study.

If the investigator determines that there is a disease progression in total lesion number or infected wart area size of the Day 1 treated area, study therapy is to be discontinued prior to 98 days of treatment.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts.
Study Start Date : January 2015
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Arm Intervention/treatment
Active Comparator: AS101
Topical 15% AS101 gel, once a day (overnight)
Drug: 15% AS101 gel
Administration of Topical 15% AS101 once a day (overnight)

Placebo Comparator: Vehicle
Vehicle, Once a day topical application (Overnight)
Drug: Vehicle
Administration of Vehicle once a day (overnight)

Primary Outcome Measures :
  1. Change in number of warts and infected area size (absolute and percent) as compared to Day 1. [ Time Frame: within 14 weeks of treatment ]

Secondary Outcome Measures :
  1. Assessment of safety of AS101 15% gel as expressed by the occurence of local topical reactions such as erythema and edema and systemic reactions to the treatment [ Time Frame: within 14 weeks of treatment and 3 months of follow up ]
  2. In complete responders assessment of time to complete clearance of warts. [ Time Frame: within 14 weeks of treatment ]
  3. In complete responders assessment of recurrence rate and time to recurrence. [ Time Frame: Within 3 months of follow up post treatment ]
  4. Collection of patient's satisfaction data from treatment etc. [ Time Frame: within 14 weeks of treatment ]
  5. Assessment of tolerability to the 15% AS101 gel as expressed by patient's itching and burning reports. [ Time Frame: within 14 weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Women at least 18 years of age and in good health;
  2. Must sign an ethics committee approved informed consent form and be able to adhere to study visits and protocol requirements;
  3. Women must agree to avoid sexual contact while the gel is on their skin;
  4. All study participants who are sexually active must use a protection method of contraception during treatment and for 60 days after completion of treatment;
  5. Patients with clinical diagnosis of external genital warts, in the external genitalia including vulva (labia minora and majora), inguinal folds, pubic area, perineum, perianal, or buttocks areas; two or more distinct external genital warts, and wart area to be treated that is equal to or less than 10 cm2.

Exclusion criteria:

  1. Participation in an investigational trial within 30 days prior to screening;
  2. Previous participation in a trial investigating AS101 for any indication;
  3. Topical treatment for genital warts within 14 days of screening;
  4. Cutaneous surgery, including cryosurgery or laser, to genital area within 30 days of screening;
  5. Skin irritations of other clinical signs or symptoms associated with prior therapy.
  6. Topical and systemic immunosuppressive or immunomodulatory medications (including corticosteroids) within 30 days prior to screening, and while on study;
  7. Current active infection with herpes genitalis or history of herpes genitalis infection within the last 30 days prior to screening (patients on long-term suppressive antiviral therapy are eligible);
  8. Diagnosis of high-grade cervical dysplasia;
  9. Internal anogenital, vaginal, cervical warts or urethral meatal warts requiring treatment;
  10. Chronic or acute skin condition that might interfere with the treatment or evaluation of study drug effect;
  11. Screening laboratory tests results from a complete blood count (CBC), chemistry panel and urine pregnancy test obtained during screening:

    1. Must be within the site laboratory's defined normal reference ranges, and/or according to the Investigator's decision;
    2. Urine pregnancy test in females of childbearing potential must be negative;
    3. Inadequate renal function: Serum Creatinine >2.0mg/dL (>2.0 ULN);
    4. Inadequate liver function: Serum (total) Bilirubin >2 mg/dl or ALT and/or AST greater than two times the upper limit of the reference range.
  12. Uncontrolled infection or acute severe febrile illness;
  13. Diagnosed as having uncontrolled cardiovascular, hematological, hepatic, neurological, renal, endocrine, vascular, autoimmune, or gastrointestinal abnormalities or disease;
  14. Pregnant or lactating;
  15. Known allergy to AS101 or any component of the investigational formulation; or
  16. Subjects with any other clinically significant medical condition, psychiatric condition or laboratory abnormality which would, in the judgment of the Investigator, interfere with the subject's ability to participate and comply with the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01943630

Contact: BioMas Ltd +972-72-2204004

Ha'Emek Medical Center, Department of Gynecology and obstetrics Recruiting
Afula, Israel, 1834111
Contact: Shabtai Romano, MD    +972-4-6494331   
Principal Investigator: Shabtai Romano, MD         
Sub-Investigator: Moshe Bustan, MD         
Kaplan Medical Center, Department of Gynecology Recruiting
Rehovot, Israel, 76100
Contact: Alon Ben-Arie, MD    972-8-9441325   
Principal Investigator: Alon Ben-Arie, MD         
Sub-Investigator: Dora Milman, MD         
Ziv Medical Center, Department of Gynecology and obstetrics Recruiting
Safed, Israel, 13100
Contact: Inbar Ben-Shachar, MD    972-4-6828959   
Principal Investigator: Inbar Ben-Shachar, MD         
Sub-Investigator: David Peleg, MD         
Tel-Aviv Sourasky Medical Center, Department of Gynecology Recruiting
Tel-Aviv, Israel, 64239
Contact: Dan Grisaru, MD PhD    +972-3-6925604   
Principal Investigator: Dan Grisaru, MD PhD Prof         
Sub-Investigator: Jacob Niv, MD         
Sub-Investigator: Yifat Oxhorn, MD         
Sponsors and Collaborators
BioMAS Ltd
Principal Investigator: Shabtai Romano, MD Ha'Emek Medical center, Department of Gynecology & obstetrics

Responsible Party: BioMAS Ltd Identifier: NCT01943630     History of Changes
Other Study ID Numbers: AS101-IL#002
First Posted: September 17, 2013    Key Record Dates
Last Update Posted: November 1, 2016
Last Verified: October 2016

Keywords provided by BioMAS Ltd:
HPV condyloma acuminata

Additional relevant MeSH terms:
Condylomata Acuminata
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Ammonium trichloro(dioxoethylene-O,O'-)tellurate
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Radiation-Protective Agents
Protective Agents